KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $2.0 billion.

  • CRISPR Therapeutics AG's Cash & Current Investments rose 378.18% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 378.18%. This contributed to the annual value of $2.0 billion for FY2025, which is 378.18% up from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Cash & Current Investments stood at $2.0 billion, which was up 378.18% from $1.9 billion recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Cash & Current Investments peaked at $2.6 billion during Q2 2021, and registered a low of $1.7 billion during Q4 2023.
  • Its 5-year average for Cash & Current Investments is $2.0 billion, with a median of $1.9 billion in 2024.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Cash & Current Investments soared by 17399.57% in 2021, and later crashed by 2369.82% in 2022.
  • CRISPR Therapeutics AG's Cash & Current Investments (Quarter) stood at $2.4 billion in 2021, then decreased by 23.7% to $1.8 billion in 2022, then decreased by 6.7% to $1.7 billion in 2023, then rose by 12.41% to $1.9 billion in 2024, then grew by 3.78% to $2.0 billion in 2025.
  • Its Cash & Current Investments stands at $2.0 billion for Q4 2025, versus $1.9 billion for Q3 2025 and $1.7 billion for Q2 2025.